Physician profile
George Patrick Wolfe
NPI 1730148602
$8,724.62
in general payments reported to CMS, 2019-2025
41 companies · $627 in 2025
The $627 reported for 2025 was more than what 77% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,485 · 2022: $2,219 · 2023: $2,078 · 2024: $2,315 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,931 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,930.50 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,014.93 | 2021-2025 | |
| Lilly USA, LLC | $997.14 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $858.37 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $728.71 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $706.50 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $567.45 | 2021-2025 | Jardiance, Ofev |
| Astellas Pharma US INC | $566.21 | 2021-2024 | Veozah, Myrbetriq |
| Abbott Laboratories | $417.77 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $380.84 | 2021-2024 | |
| Amgen INC. | $264.94 | 2021-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $242.32 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $164.10 | 2021-2022 | |
| Corcept Therapeutics | $151.12 | 2021-2025 | Korlym |
| Exact Sciences Corporation | $137.82 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceuticals, INC. | $136.91 | 2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.